

Index

a

- ABCC4(MRP4) 109
- ABCC5 (MRP5) 109
- ABCC11 (MRP8) 109
- Abemaciclib 190, 278
- acceptor–donor based heterocyclic
 - compounds 208–210
- acetylated polyamines 37
- active-control treatment impact 227
- acute leukemia 107–109, 227
- acute myelogenous leukemia (AML) 107–111
- adjuvant polychemotherapy 107
- adjuvant therapy 158, 159, 232, 275, 276, 279
- Affordable Care Act 239
- age-triggered LOH 47
- aging 47–48
- agmatinase 37
- AI-CAD 144
- Allred score 186
- anastrozole 188, 189, 276, 278, 279
- aneuploidy 36, 45
- angiogenesis inhibitors 167, 281–284
- antagonist molecules 183
- anthracycline 107, 108, 159, 166, 167, 170,
 - 193, 253, 275–277
- anthraquinone-loaded liposomes 165, 258
- antiandrogen drugs 194
- antibodies 16, 17, 74, 97, 117, 164, 166, 167,
 - 193, 257, 262, 275, 276, 279, 284
- antibody-drug conjugates (ADCs) 117, 167,
 - 193, 276
- anti-cancer formulations 117
- anti-estrogen therapy 68, 275
- antineoplastic anticancer immunotherapy
 - against programmed death-ligand
 - (PD-L1) receptor-positive TNBC 70
- antiretrovirals 97
- apatinib (ATN) 75
- apoptosis 43, 48, 49, 73, 109–111, 120, 122,
 - 123, 157, 160, 161, 169
- apoptotic cell death 76, 169
- apparent diffusion coefficient (ADC) values 8
- aptamer-coupled lipid nanosystem 162
- aptamers 263
- AraC 108
- area under the receiver operating characteristic
 - curve (AUROC) 8
- Arginase 37
- Arimidex (anastrozole) 188
- Aromasin (exemestane) 188
- aromatase inhibitors (AIs) 188, 190, 275
- artificial intelligence (AI) 203
 - applications in medicine 140
 - breast cancer screening and
 - diagnosis 136–138
 - breast tumor detection 137
 - breast tumor identification programs 136
 - clinical care 143
 - clinical utility 137
 - digital screening mammography 140
 - email sifting and computer vision 134
 - FFDM 142
 - four-point mammography 136
 - full-field digital
 - mammography 134, 136–137
 - genetics and contemporary imaging 134

artificial intelligence (AI) (*contd.*)

- human brain functioning 138
- illness screening and prediction 138
- image classification 141
- imaging techniques 136
- imaging tools 136
- magnetic resonance imaging 134
- malignant neoplasms 136
- mammography screening 136, 140
 - in breast cancer 133
 - and DBT evaluation 137
 - procedures 142
 - test 134
- medical imaging data 140–141
- supplemental imaging tools 136
- technology 6
- validation 142

ataxia telangiectasia-mutated (ATM) 38

atezolizumab 70, 170, 193, 281

ATP-binding cassettes (ABCB1, ABCC2, ABCG2) 195

ATP binding cassette transporters 109

ATP hydrolysis 242

Au-nano matryoshkas 160

Aurolase[®] (gold nanoparticles) 119

Aurora A centrosome pool 39

automated image analysis methods 138

autophagy 49, 120

AX09 164

axillary lymphadenopathy 7

b

B-ALL 108, 109

basal-like subtype 192

basal-like TNBC 154

basal-like tumors 192

BC, common drug 275

BC subtypes 154, 155, 250, 252, 263

benefit-risk ratio 107

big training data 141

Bim expression 109

bioinformatics 264

biomedical sciences 261

biopharmaceutical companies 135

biosensor 16

bipolar cell division 50

BRCA1 15

BRCA2 15

BRCA2 (PALB2) 47

BRCA alteration 135

BRCA1 and BRCA2 pathways 50

BRCA1 binding 47

BRCA1/BRCA2 mutants 36

BRCA1/2 mutations 88, 170, 249

BRCA2 mutations 40, 46

BRCA proteins (tumor suppressors) 47

BRCA2 recruitment 47

breast cancer (BC) 273

- angiogenesis inhibitors 281
- histological and molecular research 273
- histone deacetylation inhibitors 281
- novel therapeutic targets 277
- subtypes of 274
- targeted therapy 276
 - drug repurposing 276–278
 - HER2 inhibitors 278–280
 - immunotherapy 280–281
 - PARP inhibitors 280
- therapeutic approaches 274
 - chemotherapy 276
 - hormonotherapy 275–276

BReast CAncergene (BRCA) 1 and 2 mutagens 167

breast cancer oncology product development programmes 229

breast cancer-related lymphedema 238

breast cancer risk, smoking initiation 202

breast cancer survival analysis 249

breast cancer therapy 74, 124, 202

BreastNet18 model 6

breast tumor indicators 4

c

CAD algorithms for breast imaging

- modalities 143

CAD programs 137

CAD systems 140

cAMP 108

cAMP-associated proteins 109

cAMP-dependent regulatory proteins 109

cAMP efflux inhibitor compounds 111

cAMP response elements (CRE) 110

cAMP signaling 108, 110

cAMP signaling in cell proliferation

- apoptosis, and survival 111

cAMP within endosomes 108

- cancer clinical trial end points 226
- cancerous stem cells (CSC) 274
- cancer-related financial toxicity 238–239
- capecitabine 193
- carbon allotropes 164
- carbon nanotubes (CNTs) 164
- carboplatin 106
- carboplatin with docetaxel/paclitaxel 159
- CBER (Center for Biologics Evaluation and Research) on tumour vaccines and cellular therapies 226
- CD24 15
- CD44 15
- CDK4/6 inhibitor 278
- CDK-inhibitors 36
- CD-R and DVD-R optical storage discs 212
- cell cycle progression 36, 88, 279
- cell differentiation pathway 192
- cell growth 65, 88, 122, 181, 277
- centrosomes 39–40
 - amplification 47
 - clustering 50
 - duplication 47
- charged lipids 256
- checkpoint inactivation and replication stress 36
- chemically modified tryptone-stabilized gold NPs 161
- chemiluminescence immunoassay 4
- chemo-photothermal therapy 210
- chemoresistance (CRs) 70
- chemotherapy 68, 106, 187, 250, 254, 276
- chitosan (CH) 76
- CHK2-dependent phosphorylation of BRCA1 at centrosomes 39
- chromosome aberration 36
- chromothripsis 46
- CircRNA 15
- circulating cell-free DNA (ccfDNA) 15
- circulating RNA (circRNA) 15
- circulating tumor cells (CTCs) 15, 16
- circulating tumor DNA (ctDNA) 15
- Claudine's low subtype of triple-negative breast cancer 192
- clinical trials 230
 - analysis 228
 - design and analysis 227
 - endpoints 223
 - in TNBC 196
- CNNs with multiple hidden layers 142
- cobalt ferrite NPs (CFNPs) 161
- co-chaperones and client protein binding 242
- color Doppler ultrasound 7
- combinatorial chemo-photodynamic therapy method 121
- compassionate usage 231
- compressive sensing (CS) techniques 12
- computational techniques 135
- computer-aided design (CAD) tools 137
- computer aided detection (CAD) 6, 137
- computer-aided diagnosis 137
- computer-assisted diagnosis 137
- computer-assisted medical image analysis 137
- computer vision 138
- confocal microwave imaging (CMI) 12
- conservation of stalled replication forks 46–47
- consolidation therapy 108
- continuous wave (CW) single-or multi-frequency electromagnetic signals 12
- contrast-enhanced mammography (CEM) 5
- conventional CAD 137
- convolutional layer's feature map 139
- convolutional neural networks (CNNs) 137–140
- Cox regression analysis 107
- CP-673451 50
- CREATE-X 167
- CREB signaling 109
- CREB with nuclear respiratory factors (NRF) 110
- CRISPR 261
- CS-based MWT technique 12
- CSPG4 (chondroitin sulfate proteoglycan) protein signaling pathway 158
- CXCR4 110
- CXCR7 110
- CYAD-101 trial 232
- cybersecurity 143
- cyclic voltammetry (CV) 17
- cyclin-dependent kinase (Cdk) inhibitor protein 88
- CYP2D6 194
- CYP19 gene 188
- cytarabine 201
- cytosine arabinoside 108

cytosol and Plasma membrane 110
 cytotoxic therapies 170
 cytotoxic T-lymphocyte associated antigen
 (CTLA-4) 281

d

data unsupervised learning 140
 daunorubicin 74
 DaunoXome® 117
 DDR's endurance 48
 deep belief net (DBN) with hidden layers
 during pretraining 141
 deep learning (DL) 135
 deep learning algorithms 203
 deep neural networks 135
 dendrimers 117, 163–164, 255–256
 Depocyt® 117
 DESTINY-Breast03 (NCT03529110) 232
 DFMO 49
 diamidino-2-phenylindole (DAPI) staining 75
 differential pulse voltammetry (DPV) 17
 digital breast tomosynthesis (DBT) 5, 136–137
 dihydropyrimidine dehydrogenase
 genotype 195
 disease-free interval (DFI) 225
 disease-free survival (DFS)
 improvements 224
 DL-based CAD system 140
 DL learning model training 140
 DL vision-based recognition and
 detection 140
 DMPLN 260
 DNA and hormone binding 184
 DNA damage 36
 agents 191
 checkpoints 35
 or mutation 48
 DNA lesion resistance 46
 DNA repair 40
 defects 46
 genes 42
 mechanisms 47, 50
 system 35
 DNA replication 50
 duplicate copy of the genome 35
 exogenous and endogenous factors 35
 initiation 36
 replication stress 35

 without extra ssDNA 46
 DNA synthesis 38
 DNA-targeting platinum drug 106
 docetaxel + capecitabine 159
 dolutegravir (DTG) 97
 donor-acceptor heterocyclic compounds 212
 donor acceptor (D-A) molecule 208
 DOX-loaded cholecalciferol-PEG conjugate-
 based nano micelles 163
 doxorubicin 201
 doxorubicin (Doxil®) for ovarian cancer 117
 doxorubicin-hyaluronan (DOX-HA) SPIONPs
 therapeutic efficacy in TNBC cell
 lines 161
Drosophila melanogaster larvae 237
 drug delivery efficacy 156
 drug delivery systems 117
 drug repurposing, BC 276
 ductal carcinomas 67
 ductal hyper-proliferation 66
 ductal or lobular carcinomas 67
 dynamic contrast-enhanced magnetic
 resonance imaging (DCE-MRI) 8

e

early breast cancer (EBC) 225
 detection 3
 EC1456 (drug-folate conjugates) 162
 edelfolsine NE (ET-NEs) 258
 EGFR gene 157
 electrical pulse (EP)-mediated turmeric AgNPs
 therapy 161
 electrochemical biosensors 16–18
 electrochemical impedance spectroscopy
 (EIS) 17
 electrochemical nanobiosensors 17
 elemene NE (E-NE) 258
 emodin 74
 endocrine therapy 184, 185, 275
 endogenous replication stress 47
 endogenous retroviruses 96, 97
 endpoints based on tumour evaluations 225
 enhanced permeability and retention effect
 (EPR) 117
 enzyme-linked immunosorbent assay 4
 epidermal growth factor 2, 36, 66
 epidermal growth factor (EGF) 85
 group of hormones 85

epigenetic silencing 93
 epipodophyllotoxins 107
 Epithelial Cell Adhesion Molecule (EpCAM)
 binding aptamer sphere 167
 epithelial to mesenchymal cells (EMTs) 156
 ErbB 86
 ErbB1 85
 ErbB2 85
 ErbB3 85
 ErbB4 85
 Erb-b gene 86
 ErbB receptor family 85
 ER/ERP mediated gene transcription 184
 Escapenet 167
 estradiol (E2) 37
 estrogen 182–183
 estrogen receptor (ER) 36, 65, 182, 183, 273
 positive 185
 estrogen receptor alpha (ER α) 66
 estrogen receptor down regulators
 (ERDs) 188
 ETV6-RUNX1 108
 European validations for breast tumor
 identification and investigation 136
 excision repair cross-complementing group 1
 (ERCC1) 195
 excision repair cross-complementing group 2
 (ERCC2) 195
 exemestane 189
 exosomes 261–262
 expanded access 231

f

failed post-replication repair 40
 FANCD2-deficient cells 46
 FDA's accelerated approval program 228
 FDA's Oncology Program 226
 feature filtration 140
 Federal Food, Drug, and Cosmetic Act (FD&C
 Act) 223
 Femara (letrozole) 188
 fertility preservation 230
 field-effect biosensor (FET) 17
 FLAG 108
 5-fluorouracil (5-FU) 277
 fluoropyrimidine 195
 folate receptor alpha (FOLR1) 168
 folded graphene 164

Food and Drug Administration (FDA) 70,
 230, 232
 approvals 233
 approved and clinical trial drugs 250
 approved targeted therapies for TNBC 170
 approved therapies 232
 recommendations 230–31
 fucose-anchored-LPH-NPs 260
 full-field digital mammography (FFDM) 6
 picture 141
 fulversant 189
 fulvestrant 189, 191, 275
 functional polymers 212
 FZD6 receptor 156

g

G α -coupled H2-histamine receptor
 signalling 110
 G α s-coupled G protein coupled with estrogen
 receptor 111
 gelatin (GTN) 76
 gemcitabine (GCT) 72, 193
 gene expression patterns 66
 generative adversarial networks 140
 gene therapies for BC therapeutics and
 diagnostics 250
 genome instability 35
 genomic aberrations and instability 40–41
 genomic alteration in breast
 tumors 194
 genomic instability 48, 50
 GeparNUEVO 166
 geriatric assessment 225
 GI in cancer development 48
 Global Breast Cancer Initiative in 2021, 249
 Glutathione S-transferases gene
 polymorphism 195
 gold nanoparticles (AuNPs) 161, 255
 gold nanospheres (AuNSPs) 72
 G1 phase 88
 graphene-based nanosystems
 (GrNSs) 119–120
 griseofulvin 50

h

H2AX 37
 heat shock proteins (HSPs)
 cellular protection and proteostasis 238

- heat shock proteins (HSPs) (*contd.*)
 - classification 237
 - discovery 237
 - intracellular concentration 237
 - molecular chaperones 237
 - molecular-like machinery 238
 - protein biogenesis, folding, translocation,
 - and protein localization 238
 - protein folding stages 238
 - proteostasis role in cellular function and cell
 - viability 238
 - role of 237
 - structure-functional-features
 - Hsp40 239
 - Hsp60 239–240
 - Hsp70 240–241
 - Hsp70-2 240
 - Hsp90 241–242
 - HSP40/DnaJ 239
 - during protein folding 243
 - signal transduction 242
 - Hedgehog signaling pathway 156
 - Hensify[®] (hafnium oxide nanoparticle) 117
 - HER-1 85
 - HER2 86–87
 - HER-2 85
 - HER3 87
 - HER-3 85
 - HER-4 85
 - Herceptin (HCT) 74
 - HER2 dimerization 87–88
 - HER2 gene 88
 - HER2-HER3 heterodimer 87–88
 - HER2 inhibitors 278
 - HER2 protein 88
 - HER proteins 86
 - HER proteins signaling activity 87
 - HERV-derived lncRNA 95
 - HERV expression 94, 96–97
 - HERV expression and pathology 97
 - high-power lasers 203
 - High-Resolution Magic Angle Spinning
 (HRMAS) approach 8
 - HIPPO pathway 169
 - histone deacetylase (HDAC)
 - inhibitors 209, 281
 - histone modifications 40
 - HLTF 47
 - Holographic Microwave Imaging (HMI) 14
 - homo heterodimerization 87
 - hormonal therapy types 187
 - hormone/endocrine therapy 187
 - hormone receptor-negative
 - (or hormone-negative) breast
 - cancers 186
 - hormone receptor-negative tumors 185
 - hormone receptor-positive (or hormone-
 positive) breast cancer cells 186
 - hormone receptors 105, 252
 - hormones 181
 - hormone therapy 68, 187, 190
 - drugs classification 187
 - limitations 190–191
 - related toxicity 194
 - and surgery 106
 - hormonotherapy 275
 - HPV (human papillomavirus) vaccine
 - trials 226
 - H-score semi-quantitative scoring system 186
 - Hsp40 239, 241
 - Hsp60 240
 - HSP70 243
 - Hsp70 240–242
 - HSP90 243
 - Hsp90 241–242
 - HSP40/DnaJ 239
 - Hsp90 structure and its domain 242
 - human endogenous retroviruses (HERVs) 93
 - triple negative breast cancer 95–97
 - human epidermal growth factor-2(HER-2) 65,
 184, 273
 - human epidermal growth factor receptors
 - (HERs) 85–88
 - Human Genome Project 93
 - human intelligence 138
 - hybrid D-A polymer particles (H-DAPPs) 211
 - hydrogels (HGLs) 74
 - hydrolysis of cyclic nucleotides 109
 - hypermethylation 47
 - hyperpolarized ¹³C MRI (HP ¹³C
 MRI) 8
- i**
- icAMP 109
 - icAMP regulation in hematopoietic
 malignancies 109

ICER downregulation 109
 IDC-NST 66
 image databases 143
 image-guided gene therapy (IGGT) 120
 ImageNet32 141
 2012 ImageNet Large Scale Visual Recognition Challenge 138
 imaging techniques
 benefits and drawbacks 4–5
 IMMU-132 (drug-antibody conjugates) 162
 immune cells 154
 immune checkpoint inhibitors (ICIs) 161, 193, 281
 immune infiltration in breast cancer tumor 96
 immune therapy 193
 immunoconjugates 193
 immunohistochemistry (IHC) 154
 estimation 154
 examination of BC 153
 test 186
 immunomodulatory (IM) subtype 192
 immunotherapy 106, 119, 191, 193, 250, 276
 BC 280
 immunotherapy with immune check
 inhibitors 167
 indocyanine green (ICG) 210
 infiltrating ductal carcinoma (IDC) 238
 insulin-like growth factor receptor 1, 87
 inter crossing system (ISC) 208
 intermediate clinical endpoint 224
 intrinsic RFBs 37
 intrinsic toxicity reduction 69
 invasive breast cancers 66
 invasive carcinoma 67
 invasive lobular carcinomas (ILC) 67
 invasive techniques 201
 in vivo genetic screening 169
 irinotecan 195
 iron oxide 161

k

90-kDa heat shock protein (Hsp90) 241
 KRAB-containing zinc-finger proteins 93

l

laser irradiation 121
 later-phase efficacy trials 223
 leading-strand polymerase blockage 38

letrozole 189
 leukaemia chemotherapeutic agents
 (LCA) 108
 leukaemia treatment 108
 leukemia 107
 leukemia cells 111
 ligands 262–263
 functionalised nanoparticles for
 treatment 264
 inclusion for nanoparticle targeted
 delivery 262–263
 interaction 86
 light-based nanotechnology for breast
 cancer 120–122
 linear sweep voltammetry (LSV) 17
 lipid based nano formulations 250
 lipid-based nanoparticles (LNPs)
 256–261
 advantages and limitations 257
 lipid polymer hybrid nanoparticles
 (LPH-NPs) 260–261
 liposomal formulation 165
 liposomes 117, 155, 169, 256, 258
 liquid biopsy 4
 liquid crystals 212
 LncRNA 15, 95
 lobular carcinomas 67
 lobules 181
 LOF mutations in PALB2 47
 long non-coding RNAs (lncRNAs)
 15, 95
 luminal androgen receptor (LAR)
 subtype 193
 lupron 189
 luteinizing hormone-releasing hormone agents
 (LHRH) 189–190
 lymphatic system 238
 lymphedema 238
 lymphedema management 239
 lysyl oxidase 1 (LOX) 165

m

mAbs 162
 machine learning (ML) 134, 203
 data-guided technique 138
 earning model 142
 models 135
 model training data 134

- MagForce[®] (iron oxide nanoparticles) 119
 - magnetic IONPs 161
 - magnetic Resonance Diffusion Weighted (MRDW) 8
 - magnetic resonance elastography (MRE) 10
 - Magnetic Resonance Imaging (MRI) 68
 - magnetic resonance imaging (MRI) 9, 10
 - magnetic resonance spectroscopy (MRS) 8
 - mammalian target of rapamycin (MTOR) inhibitors 157
 - mammary stem cells (MaSC) 274
 - mammography (MG) 4, 68
 - based screening programme 133
 - screening 133
 - management strategies 68
 - manifold randomized type clinical trials 137
 - Marqibo[®] 117
 - MCC (mitotic checkpoint complex) 38
 - MCF-7 cell surface proteins 17
 - MCM27 36
 - MDA-MB-231 cells viability 260
 - medical radiology fraternity 140
 - medical resources 136
 - Mepact[®] 117
 - mesenchymal stem-like subtype (MSL) 192
 - mesenchymal subtype 192
 - metabolic syndrome 66
 - metallic nanoparticles 255
 - metastatic breast cancer (MBC) 182, 225
 - methylene tetrahydrofolate reductase 195
 - microbubbles (MB) 75
 - MicroPure 7
 - MicroRNA 15
 - microtubule depolymerization 50
 - microtubules 39
 - microvessel density (MvD) 75
 - microwave breast imaging 11
 - microwave imaging (MWI) 10, 11
 - microwave Imaging via Space-Time (MIST) beamforming 13
 - microwave tomography (MWT) 11
 - mifamurtide 201
 - mitochondrial cAMP-PKA signaling 110
 - mitochondrial folate pathway 37
 - mitogen-activated protein kinase (MAPK) 85, 87
 - mitomycin (MMC) 260
 - mitotic checkpoint 35
 - mitoxantrone 107
 - mixed-lineage leukaemia (KMT2A) gene rearrangement 108
 - MLN4924 49
 - modified J-score 186
 - molecular biology methods 4
 - molecular biology of TNBC 96, 155
 - molecularly imprinted polymers (MIPs) 19
 - molecular mechanism of genomic instability 42–45
 - molecular overlapping between triple-negative and basal-like subtypes of BC 154
 - mTOR pathway 169
 - MUC1 (CA15-3) 15
 - multiple stacked layers 139
 - multipolar mitosis 47
 - multi-static adaptive (MSA) system 13
 - MYC genes 37
 - MYC-ODC-linked polyamine synthesis pathway 49
 - MYC overexpression 37
 - Myocet[®] 117
- n**
- nab-paclitaxel (N-PTX) with atezolizumab (ATZ) combination 70
 - nanocarriers 250
 - clinical trials 77
 - nanocarrier systems 117
 - nanocomposites 163
 - nanoconjugates 162
 - nanodiamonds (NDs) 69, 162
 - nano emulsions (NE) 117, 258
 - nanoformulations, for TNBC treatment 160
 - nanomaterial carriers 121
 - nano-matryoshkas 163
 - nanomedicine 155
 - complications of cytotoxicity 159
 - surface-area-to-volume ratio 156
 - nanomedicines and molecular pathways in TNBC treatment 155
 - nanomedicines FDA approved and undergoing clinical trials 251
 - nanoparticle-based therapeutics
 - surgical intervention 250
 - nanoparticle delivery system 167
 - nanoparticles 117

- nanoparticles (Abraxane®) 155
 - nanoparticles (NPs) 160
 - TNBC 252
 - biological system 253
 - chemotherapeutic agents 252
 - clinical trials 254
 - delivery vehicle 253
 - guided surgeries 253
 - molecular heterogeneity 252
 - preclinical and clinical trials 254
 - properties 253
 - substances with fluorescence properties 253
 - treatment outcomes 253
 - tumor microenvironment and heterogeneity 250
 - nanoparticle therapies for cancer 118–119
 - nanostuctured lipid carriers (NLC) 259–260
 - nanotechnologies-based
 - nanoformulations 156
 - nanotechnology 155, 212
 - nanotechnology-based breast cancer management strategies 119
 - nanotechnology-based drug delivery systems (DDSs) 159
 - nanotechnology-based treatment for TNBC 261
 - nanotechnology in cancer management 117
 - nanotherapeutics
 - benign or metastatic carcinoma 66
 - for breast cancer treatment and metastasis 69–70
 - clinical trials 76–77
 - estrogen and progesterone hormone receptor 76
 - medical diagnosis and therapy 77
 - PTX albumin 76
 - National Centre of Nanoscience China 76
 - natural language processing 138
 - ND-based delivery systems against breast cancer models 69–70
 - NDs delivery system of polyglycerol 69
 - NEO adjuvant modeling 169
 - neoadjuvant therapy 158–159
 - NEON-2 trial 232
 - neural networks 135, 139
 - in medical imaging 135
 - next-generation sequencing (NGS) 191
 - Nicotine 202
 - noninferiority (NI) trial 227
 - non-invasive carcinoma 67, 182
 - non-invasive techniques 201
 - non-invasive type, ductal carcinoma in-situ (DCIS) 238
 - non-linear activation function 139
 - non-optics 212
 - norganic nanoparticles (IONPs) 72–73, 250
 - notch signaling pathway 156
 - Novel Dye Conjugate (nDC) 211
 - nuclear fragmentation 76
 - nuclear Ki67 staining 192
 - nucleic acid-based gene therapy 119
 - nucleic acids (NAs) 262
 - nucleic acid tumor markers 15
 - NUDT1 49
- O**
- obesity 66
 - Office of Cancer Drug Products (OODP) 226
 - Office of Hematology and Oncology Products (OHOP) 226
 - oncogene-induced senescence (OIS) 48
 - oncologic decision-making 66
 - Oncologic Drugs Advisory Committee (ODAC) 224
 - oncology drug development, early phase clinical trials 223
 - oncology, survival improvement 224
 - Onivyde™ 117
 - oophorectomy 190
 - optical biosensors 17, 19
 - osteonecrosis 108
 - ovarian suppression 190
- P**
- P27 88
 - paclitaxel 201
 - paclitaxel-DART NPs 160
 - Palbociclib 190, 278
 - PAMAM dendrimer 167
 - parallel deep neural networks 138
 - PARP inhibitors 48, 106, 280
 - passive/active targeting of nanoparticles 117
 - PDE activity 109
 - PDGFR-inhibitors 50

- PD-L1 281
 - PD-1/PD-L1 signaling 164
 - PDT using Jablonski diagram 209
 - pembrolizumab 193
 - peptides 263
 - peroxisome proliferator-activated receptor (PGC-1 α) 110
 - persistent stalled replication forks 47
 - PG-DOX-NDs 70
 - pharmacogenetics 194
 - pharmacogenomics markers 194
 - phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K) 87
 - phosphatidylinositol 3-kinase (PI3K) 88
 - phosphodiesterase 109
 - phosphoinositide-3-kinase (PI3K)/Akt signalling pathway 85
 - phosphorylated tyrosine residues 86
 - photoconductors for xenography 212
 - photodynamic therapy (PDT) 120–121
 - photoelectrochemical (PEC) biosensors 17
 - photosensitizers (PS) 120, 204
 - phototherapy 120
 - photothermal agents (PTA) 122
 - photothermal conversion, biomedical applications 122
 - photothermal therapeutic nanomaterials 122
 - photothermal therapy (PTT) 76, 120, 122, 203–204, 207–208
 - photo-triggered therapy 120
 - photovoltaic materials for solar cells 212
 - phthalocyanines 211–212
 - PI3K/Akt pathway 279
 - PI3K inhibitors 279
 - p27Kip1 protein 88
 - PLGA-containing nanoparticles 167
 - PLK1-inhibiting medicines 48
 - POLH mutations 47
 - polyamines 37, 49
 - poly(amidoamine) (PAMAM) dendrimers 256
 - polymalic acid-based nano biopolymers 168
 - polymalic acid-based nanoconjugates 168
 - polymer-based nanoparticles (PBNPs) 71
 - polymer-drug conjugates 162
 - polymeric micelles (PM) 163, 250
 - polymeric nanoparticles 117, 250
 - polymorphisms in HERV loci 94
 - poly (ADP-Ribose) polymerase (PARP) inhibitors 157
 - polyubiquitylation of chromatin-bound PCNA 47
 - pol ζ -deficient cells 47
 - porphyrin 211
 - post-transcriptional inhibitory effect of p27 88
 - pre-cancer or carcinoma in situ (CIS) 182
 - premature replication 36
 - premenopausal women, treatment of breast cancer 229
 - progesterone 182
 - progesterone receptor (PR) 36, 65–66, 182, 184, 273
 - positive 185
 - programmed cell death receptor 1 (PD-1) 281
 - proliferation pathway 192
 - proTAME 50
 - protein kinase C (PKC) 85, 87
 - protein mislocalization and fast degradation 87
 - proteolytic enzymes 239
 - proteomics 4
 - PRR (Post-Replication Repair) pathways 37
 - PTT induced inhibition of cancer growth 203
 - puberty 181
 - PubMed search 97
 - puerarin nanoemulsion (NanoPue) 258
- q**
- QD-based nanotechnology 162
 - quantum dots (QDs) 162
 - based optical biosensor for detection of MCF-7 cells 18
 - quartz crystal microbalance (QCM) biosensor 17
 - quinoline based QpyNHOH molecules 209
- r**
- radar based MW 12
 - RAD50 gene 96
 - radiation 187
 - radiation therapy 68, 250

- radio-based microwave imaging
 - technology 12
 - radiotherapy 106
 - raloxifene 190
 - randomized controlled trials 227
 - ras-mitogen activated protein kinase (MAPK) 88
 - reactive oxygen species (ROS) 35
 - receptor targeting molecules 117
 - receptor tyrosine kinases (RTK) 88
 - rectified linear unit (ReLU) 139
 - regional chromosome segregation 47
 - region-based convolutional neural network (R-CNN) 141
 - regulatory affairs drugs 223–232
 - remote organ metastases 135
 - replication dysfunction 36–40
 - replication fork balance 38
 - replication fork collisions 36
 - replication fork maintenance 37
 - replication stress 35, 40, 46–47, 49–50
 - replicative helicases 46
 - repurposing pathway 105–111
 - retina scanning assessment to computer-aided pathology 138
 - reverse transcriptase-polymerase chain reaction (q RT-PCR) test 186
 - Rev3l 47
 - RGD peptide conjugated Doxorubicin (DOX) 260
 - right to try 231–232
 - loop-associated genome instability 40
 - RNA and DNA based nanotherapeutics 261
 - RNA-based therapeutics 262
 - RNA-DNA hybrid 40
 - RNAi 262
 - RNA-Seq data 96
 - robotics 138
 - ROS1-positive metastatic non-small cell lung cancer 224
- S**
- selective estrogen-receptor response modulators (SERMs) 188
 - semi-supervised learning 138
 - senescence 48
 - SERM 275
 - Signaling pathways 157–158
 - signaling pathways 85
 - silver nanoparticles (AgNPs) 160, 255
 - single cell RNA sequencing data 264
 - siRNA-based TWIST1 silencing approach for
 - modified PAMAM-based dendrimer 164
 - siRNA-based TWIST1 silencing method 168
 - site-targeted deliverance of anti-cancer agents 156
 - small molecules 263
 - smoking cigarettes 202
 - social and economic confounding factors 249
 - solid lipid nanoparticles (SLN) 259
 - S-phase checkpoint dysfunction 38
 - S-phase development 47
 - Spindle Assembly Checkpoint (SAC) 38, 39
 - square wave voltammetry (SWV) 17
 - Src stimulation 88
 - ssDNA accumulation 46
 - stalled replication forks 46
 - stem cell identity 95
 - steroid hormone progesterone 181
 - stromal score 96
 - superparamagnetic iron oxide NPs (IONPs) 161
 - supervised learning 138
 - supportive care 225
 - surgery 106, 187
 - synergistic effect of drugs 169
 - system algorithms 137
 - systemic chemotherapy 254
- t**
- Tamoxifen 188, 190, 195, 275
 - targeted drug delivery systems 117
 - targeted therapy 68, 182
 - taxane-based chemotherapy 167, 276
 - taxanes 50
 - taxol 276
 - telomere to telomere (T2T) 93
 - tetrapyrrolic macrocycles 211
 - tetratricopeptide repeat (TPR) domains 242
 - TGF- β signaling pathway 158
 - TGF- β 1/Smad pathway 257
 - theranostics 250
 - therapeutic approaches
 - BC chemotherapy 276
 - hormonotherapy 275–276

- thermal decomposition technique 161
 - thermosensitive hydrogels (THGs) 74
 - Thiopurine 195
 - Thiopurine S-methyltransferase (TPMT) 195
 - 3D mammography 6
 - 3D vs 2D mammography 6
 - thymidylate synthetase 195
 - tissue-sensing adaptive radar (TSAR) 13
 - TNBC 96, 275, 281
 - TNBC tumor growth inhibition of these
 - PTX-loaded nanoparticles 168
 - TNBC xenografted murine models 262
 - Torin1 169
 - transcription-associated recombination 40
 - transcription-induced stress 40
 - Trans-Lesions Synthesis (TLS) 37, 47
 - translocation of pro-apoptotic Bax 109
 - transmembranes associated with
 - adenylyl cyclases (tmACs) activation 108
 - Trelstar 189
 - triphenylamine (TPA) 209
 - triple negative breast cancer (TNBC) 36, 105, 191, 273
 - clinical features 191
 - mammographic findings 191–192
 - triple-negative breast cancer cells 187
 - TROJAN 96
 - TTK (MPS1) inhibitors 49
 - T1 tumours 202
 - T3 tumours 202
 - tumorigenesis 40, 47
 - tumor marker detection methods 4
 - tumor suppressor pathway 169
 - tumour-associated macrophages (TAMs) 95
 - tyrosine kinase domain 86
- U**
- ULS-MB destruction (ULS-MB-D)
 - against TNBC 75
 - ULS-MB-DOX 75
 - ultra-crystalline diamonds 69
 - ultrasonography (US) 4, 7–8, 75, 136
 - ultrasound screening 68
 - unbalanced chromosome segregation 47
 - unbiased AI methods 142
 - United States Patent and Trademark Office (USPTO) 167
 - unsupervised learning 138
 - uridine diphosphate glucuronosyltransferase (UGT) genotype 195
 - urokinase plasminogen activator (uPA) 65
 - US Food and Drug Administration (FDA) 137, 143
 - US Food and Medicine Administration 230
- V**
- vascular endothelial growth factor (VEGF) 281
 - vasculogenic mimicry channels (VMC) 74
 - vincristine 108, 201
 - virus-like particles (VLPs) 164
 - VLP-based vaccine 164
- W**
- weakly supervised
 - learning 138
 - WHO Fact Sheets 181
 - Wnt/ β catenin 156
 - Wnt signalling pathway 274
 - World Health Organization (WHO) 3, 68
- X**
- X-ray cross-complementing group 1 (XRCC1) 195
 - X-ray mammography 68
- Z**
- Zoladex 189